Stopping statins safely: a UK guide

The statin question most patients are never asked

Statins are among the most commonly prescribed medications in the UK — approximately 8 million people take them. [1] Most were started for primary prevention (reducing cardiovascular risk in people without established disease) and reviewed very rarely thereafter. The question of whether the risk-benefit calculation still holds — years later, with different weight, different lifestyle, different age — is almost never raised in a standard GP appointment.

This is not because statins are universally appropriate long-term. It is because prescribing is easier than deprescribing, and because the cardiovascular risk conversation is uncomfortable to revisit once a prescription is running.

Primary versus secondary prevention: a critical distinction

The evidence base for statins is strongest in secondary prevention — patients who have had a heart attack, stroke, or established cardiovascular disease. In this group, statins reduce major cardiovascular events by approximately 25% relative risk and the absolute benefit is clinically meaningful. NICE recommends high-intensity statins for life in secondary prevention. [2] Stopping in this group requires a strong clinical justification and shared decision-making.

The evidence for primary prevention is more nuanced. The absolute risk reduction is smaller because baseline risk is lower. A patient with a 5% ten-year cardiovascular risk taking a statin for primary prevention has a different risk-benefit calculation from a patient with a 20% ten-year risk. NICE guidance recommends statins for primary prevention where ten-year cardiovascular risk exceeds 10%, calculated using QRISK3. [2]

The important question: when was your QRISK3 last calculated? If your risk was calculated when you were heavier, less active, hypertensive, or prediabetic — and those factors have now improved — your current ten-year risk may be substantially lower than when the statin was started. That changes the benefit side of the equation.

Side effects: what is real and what is nocebo

Muscle symptoms are the most commonly reported statin side effect. The SAMSON trial (2020) provided important evidence: in a blinded crossover design, approximately 90% of muscle symptoms attributed to statins occurred equally on placebo — a nocebo effect driven by expectation. [3] This does not mean statin muscle symptoms are never real — genuine statin myopathy exists — but it does mean that unblinded symptom attribution is unreliable. If side effects are the reason for considering stopping, a structured assessment of whether symptoms are genuinely drug-attributable is worth doing before stopping permanently.

Genuine statin myopathy — elevated CK and significant muscle weakness — warrants stopping and investigation. Statin-associated autoimmune myopathy (SAAM) is rare but real and requires specialist assessment. [4]

When stopping statins is clinically appropriate

Primary prevention with a recalculated ten-year cardiovascular risk now below 10%, after meaningful lifestyle improvement, particularly after significant weight loss. Genuine statin intolerance confirmed by rechallenge. End-of-life care or frailty where the long-term benefit of cardiovascular risk reduction is no longer relevant. Patient preference after full informed discussion of the quantified risk difference.

What stopping statins is not appropriate for: side effects that have not been properly attributed; vague discomfort with the idea of lifelong medication; secondary prevention without compelling contraindication.

Is there a risk from stopping suddenly?

Unlike SSRIs or antihypertensives, there is no pharmacological withdrawal syndrome from stopping statins abruptly. Lipids begin rising within days to weeks of stopping. Observational data suggest an association between statin discontinuation and increased cardiovascular event risk in the short term, though this is confounded by the reasons for stopping. [5] In secondary prevention, stopping without clinical justification carries real cardiovascular risk. In primary prevention with recalculated low baseline risk, the clinical significance is lower.

The role of weight loss in recalculating statin need

Significant weight loss — such as that achieved with GLP-1 medication — substantially improves multiple QRISK3 inputs: BMI, blood pressure, HDL cholesterol, HbA1c, and systolic blood pressure variability. For patients who have lost 15–20% of body weight and previously had borderline indications for statin therapy, a recalculated QRISK3 may no longer meet the prescribing threshold. A structured deprescribing review addresses exactly this — applying the same risk-benefit calculation that was used to start the statin to decide whether it still applies.